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Abstract 
Objective: To describe, and explore heterogeneity in, age at onset/diagnosis in Parkinson’s disease 
(PD) and compare mean age at onset/diagnosis in incidence studies with that in general PD research 
studies. 
 
Methods:  
We systematically reviewed studies of PD incidence. We meta-analysed mean age at onset/diagnosis 
and age-stratum-specific incidence rates. We compared age-specific incidence rates in screening 
studies in the elderly with whole-population studies. We collated mean ages at onset/diagnosis in 
clinical studies of PD in five journals July–December 2016.  
 
Results:  
In 17 studies reporting sufficient data to pool, mean age at onset/diagnosis was 69.6 years (95% CI 
68.2–71.1), but heterogeneity was high (I2=96%). In ten of these studies reporting age at diagnosis 
specifically, the pooled mean age at diagnosis was slightly higher (71.6 [95% CI 70.6–72.6]) with 
lower, but still high, heterogeneity (I2=84%). In twelve whole-population studies reporting age-
specific incidence rates, these peaked in age 70-79 (pooled incidence rate per 100,000=93.8 [95% CI 
80.3–107.6]). Heterogeneity increased with each increase in age stratum (0% in youngest to 88% in 
oldest age stratum). Pooled age-specific incidence rates in five population-based screening studies of 
older age groups were several-fold higher than in whole-population studies. The mean of the 
reported mean ages at onset/diagnosis in recently published research studies was 60.8 (SD 5.6). 
 
Conclusion:  
The mean age of onset/diagnosis PD is about 70, although this may be an underestimate due to 
under-diagnosis in the elderly. Many published studies use age-unrepresentative subjects: the effect 
of this selection bias deserves further study.  
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Introduction 
Accurate knowledge of the age-distribution and mean age at onset of Parkinson’s disease (PD) is 
important for several reasons. Firstly, it is a fundamental aspect of the disease epidemiology. 
Secondly, knowing this and other aspects of the epidemiology of PD is useful for health care 
planning as populations age.[1] Thirdly, it is important to enable the evaluation of the 
generalisability of clinical research, as many disease outcomes vary by age.[2-4]  
 
Many authoritative sources quote the mean age of onset (be it motor symptom onset or diagnosis) 
in PD to be about 60,[5, 6] and some have even quoted younger ages,[7] although one recent review 
quoted a median age of 65.[8] However data from many population-based studies demonstrate that 
the mean age of onset in PD is substantially older. This apparent underestimation of the age of onset 
in PD may be because unrepresentative patient samples were used (for example, research is often 
from specialist centres where younger patients are more likely to be seen),[9] or that opinion 
leaders tend to work in specialist clinics and see younger patients. The only reliable way to identify 
the true age distribution in a population of PD is by population-based incidence studies, studies 
which aim to identify all new cases in a defined population and time period.  
 
In this paper we used meta-analysis of incidence studies in PD to (i) describe the age distribution of 
PD at disease inception (i.e. either symptom onset or diagnosis); (ii) to explore heterogeneity in age 
at inception in these studies; and (iii) compare the mean age of inception in incidence studies with 
the mean age at inception in general research studies in PD. We have not reviewed the incidence 
rate of PD as such because an up-to-date systematic review of incidence studies was recently 
published.[10] 
 
Methods 
Systematic review 
We updated a systematic review of incidence studies we previously published in 2003.[11] We 
sought to include all studies of PD incidence: either studies of the whole population or studies 
restricted to particular age strata only if they used door-to-door screening methodologies for case 
ascertainment. We excluded studies published before 1990 (as the distinction between PD and 
atypical parkinsonism was less clear prior to this). We excluded studies which made no attempt to 
confirm diagnosis by expert review of case notes or in-person assessment. We excluded studies 
published only in abstract form, but not on basis of language. We searched electronic databases to 
identify potential studies (MEDLINE and Embase up to September 2017) and reviewed reference lists 
of relevant studies. The electronic searches are shown in Supplementary Appendix 1). References 
were de-duplicated in bibliographic software. Titles and abstracts of studies identified from the 
search strategy were reviewed by two authors, and the full text of potentially relevant articles was 
obtained. We identified 10 criteria to assess the methodological quality of the included studies, 
based on recommendations regarding incidence studies in PD[11] and previous criteria suggested for 
incidence/prevalence studies in general.[12] Methodological features, demographic characteristics, 
incidence rates, and ages at onset/diagnosis were extracted from each study by two authors 
independently, with disagreements resolved by discussion. Many studies reported age at onset 
without further clarification, which we have presumed to refer to age at motor symptom onset.  
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Some studies reported mean age at inception without reporting a measure of precision (i.e. no 
standard error, standard deviation or confidence interval). Where the number of cases in each age 
stratum were also presented we estimated the standard error of the mean by assuming each case 
had age on onset in the middle of the age stratum (and assumed age 85 in the 80+ stratum), 
assumptions which may result in slightly wider confidence intervals.  
 
Meta-analysis of age at inception 
We used Der Simonian and Laird random effects meta-analysis[13] to pool data on mean age at 
inception (i.e. at diagnosis or, where age at diagnosis not reported, age at onset) in studies of the 
incidence in the whole population. We performed sensitivity analyses of pooled age at diagnosis and 
at onset separately. Heterogeneity was measured using the I2 statistic.[14] We performed 
univariable random-effects meta-regression by mid-year of recruitment to the studies to assess 
whether age at inception varied with time.  
 
Meta-analysis of age-specific incidence rates 
In order to unravel the heterogeneity of the age at inception, we next performed random effects 
meta-analysis of age-specific incidence rates in ten-year age-bands,  restricted to studies published 
since 2000 to minimise heterogeneity in time. We also did this separately in population-screening 
studies  restricted to older age groups. We used the Rothman/Greenland method for estimating 
confidence limits for the incidence rate.[15] As the confidence interval for a rate of zero is 
undefined, in age strata in individual studies where no cases were identified we arbitrarily used an 
upper limit of confidence of 100 cases per 100,000. We compared heterogeneity between different 
age strata and compared results between studies which used door-to-door screening with those 
which used other methodologies for case ascertainment. We used pooled age-specific incidence 
rates to plot a histogram illustrating the distribution of age at inception of PD in the European 
Standard Population 2013.[16] 
 
We have followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting 
guidelines in this paper.[17] 
 
Review of published studies 
We reviewed all PD research papers published over a recent six-month period (July 2016 to 
December 2016) in three general neurology journals (Brain, JNNP, and Neurology) and two 
movement disorder journals (Movement Disorders and Parkinsonism and Related Disorders). We 
aimed to include all studies of PD patients in general, but excluded studies which were restricted to 
specific groups which may be influenced by age of onset. For example, we excluded studies 
restricted to specific age distributions, PD with specific features relating to age (e.g. PD with 
dementia – more common in older-onset disease), specific mutations, and interventional treatments 
for complex PD (more common in young-onset) but we did not exclude studies restricted by gender 
or disease stage. From each study we documented the mean age at either diagnosis or onset in the 
PD participants, if necessary calculated from the mean age at study entry and mean disease 
duration.  
 
Results 
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Twenty-nine studies were identified which reported the incidence of PD in the whole population and 
six further studies reported incidence in older age groups based on door-to-door screening. Details 
of the search results are shown in Supplementary Figure 1. Characteristics of included studies and 
their references are in Supplementary Table and results of quality assessment in Supplementary 
Appendix 2.  
 
Of the whole-population studies, 20 (69%) reported the mean age at inception (nine reported mean 
age at symptom onset only, nine mean age at disease diagnosis only, two reported both). In 17 
studies a measure of precision for the mean age at inception was either reported or estimable 
(Figure 1). The pooled mean age at inception in these studies was 69.6 years (95% CI 68.2–71.1), but 
heterogeneity was high (I2 96%). Restricting this meta-analysis to eight studies with a quality score 
greater than six did not substantially alter the mean age at inception (70.7 [95% CI 68.3–73.1]).  A 
meta-analysis of the ten studies reporting age at diagnosis gave a higher pooled mean age (71.6 
[95% CI 70.6–72.6], I2 84%) than the meta-analysis of nine studies reporting mean age at symptom 
onset (pooled mean age 68.1 [95% CI 65.8–70.4], I2 96%). There was no evidence from meta-
regression that age at inception varied with time (p=0.11).  
 
The forest plot of incidence rates by age stratum in twelve whole-population studies since 2000 is 
shown in Figure 2. Incidence rates increased steeply with increasing age until the eighth decade 
(pooled incidence rate per 100,000 in 70-79 stratum 93.7 [95% CI 79.9–107.6]) with a fall in the 80+ 
group (pooled incidence rate per 100,000 80.6 [95% CI 59.7–101.5]). However, confidence intervals 
for these two strata overlapped and four studies found the highest incidence rate in the oldest age 
group. There was also a clear rise in heterogeneity with increasing age, from 0% in the youngest age 
stratum to 86% in the oldest. A histogram of the age distribution based on the pooled incidence 
rates is shown in Supplementary Figure 2.  
 
Six age-restricted population screening studies reported age-specific incidence rates. Five of these 
reported comparable age strata to meta-analyse and these are presented separately because of 
different age bands reported (Supplementary Figure 3). Figure 3 shows a comparison which shows 
that the pooled estimates for the incidence rates in age-limited screening studies are several times 
higher than in the whole population studies, although a direct comparison was not possible due to 
different age strata analysed in the two study types. Two older-age screening studies used similar 
methodologies in the same population over different time periods and reported very different 
incidence rates,[18, 19] although the reasons for this were unclear. 
 
The results of the review of the mean age at inception in research articles are displayed in Table 1. 
Details of these articles, including exclusions, are provided in supplementary appendix 3. The mean 
of the reported mean ages at inception was 60.8 (SD 5.7) and the median mean age at inception was 
60.4 (interquartile range 57.7–63.7). The median age at inception in the excluded studies was lower 
(50.9). 
 
Discussion 
We have demonstrated that the mean age of motor onset and diagnosis of PD are about 70 in 
population-based incidence studies but this may be an underestimate, given the much higher 
incidences found in the older-age screening studies.  There is clear heterogeneity in both age at 
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inception and in incidence rates, with increasing heterogeneity in incidence rates with increasing 
age. We also found that the average mean age of inception in research studies in PD was about 60, 
demonstrating that research participants are generally unrepresentative of the population age 
distribution of PD. These results raise four questions with important implications. 
 
Firstly, why does heterogeneity increase with increasing age? One likely explanation for this is 
variability in case ascertainment in the elderly who will often be frail or have co-morbidities. Such 
individuals are less likely to be referred to a specialist with suspected PD[9] and data from other 
diseases suggest that age-related factors may lead to delayed presentations.[20, 21] Older people 
may accept more symptoms or higher disability before presenting to primary care providers and/or 
seeking onward referral to specialists. Furthermore, symptoms and signs of PD may be 
misinterpreted as normal ageing because many symptoms are non-specific and mild parkinsonian-
like signs are common in the elderly.[22, 23] Therefore older people with PD may be more difficult to 
identify in epidemiological studies than younger people and require more intensive case finding 
strategies to identify them.  
 
Another possible explanation of greater heterogeneity in the elderly is increased difficulty achieving 
accurate diagnosis in the elderly. Our personal experience is that formal diagnostic criteria are less 
useful in the elderly because exclusions from the UK PD Society Brain Bank criteria[24] such as a 
Babinski sign or early severe autonomic involvement are more common in this age group and the 
supportive criterion of excellent treatment response is less frequent, although we are unaware of 
published objective data to confirm this. In any case, different thresholds for diagnosis of PD in the 
elderly across different studies may contribute heterogeneity. These sources of heterogeneity are 
more likely to lead to underdiagnosing than over-diagnosing PD in the elderly and may cause under-
estimation of the age at inception in PD.  
 
Secondly, why are incidence rates in whole-population studies lower than in studies which screened 
small elderly populations? Each screening-based study in older adults was small and estimated 
incidence rates with wide confidence intervals. Yet the lower limits of confidence for the stratum-
specific incidence rates in these studies are still higher than the upper limits in the whole population 
studies. It is possible that these studies used inadequate methods to screen out pre-existing cases at 
the initial population screens. But given that many of those diagnosed with PD in these studies were 
reviewed by a neurologist, it seems unlikely that many previously-diagnosed cases would have been 
included in incidence rates. Non-participation in the screening phase of these studies (18 to 32%) 
may have introduced bias, but even if none of those had PD, the incidence rates would still be higher 
than in many whole-population studies. As previously discussed, difficulties with diagnostic accuracy 
may be relevant (i.e. overdiagnosis of PD due to over-interpretation of mild signs in the elderly) but 
there were broadly-consistent incidence rates across these studies and some of the studies used 
formal diagnostic criteria. Overdiagnosis in the elderly could be minimised by follow-up to see 
whether they progress like PD, by more post-mortem confirmation and by the use of FP-CIT SPECT 
imaging.  
 
Nevertheless, it seems unlikely that such methodological considerations explain such a dramatic 
difference in incidence rates between the study types. We therefore suggest that a large proportion 
of PD may remain undiagnosed in the elderly without screening, perhaps being mistaken for normal 
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ageing in some cases, or perhaps because more die from co-morbid disease before the parkinsonism 
becomes severe enough to present to medical attention. Further evidence for this comes from 
prevalence studies with population screening in which many cases have not been previously 
diagnosed (a pooled analysis of community surveys found 24% of PD subjects were previously 
undiagnosed).[25] Further investigation of the barriers to diagnosis in the elderly and the benefits of 
increased identification and treatment of this group is needed.  
 
Thirdly, is the drop-off in the trend of rising incidence seen in the oldest real or spurious? Although 
the overall pooled incidence rate in those aged 80 and over was slightly less than the rate in those 
aged 70-79, the confidence intervals overlap widely. In several studies in this review, the incidence 
rate continued to rise in the oldest old. One study found that incidence rates in the oldest declined if 
strict diagnostic criteria were applied, were stable with intermediate criteria, but rose with broad 
diagnostic criteria were used.[26] This may relate to greater difficulties distinguishing PD from other 
disorders in the elderly as discussed above. However, we cannot rule out the possibility that 
incidence rates do fall in the oldest old and more pathological studies in the elderly are required to 
clarify this.  
 
Fourthly, what are the implications of the under-representation of the elderly in most research 
studies? There is little doubt that many published studies of PD use relatively-younger-onset 
patients. This has previously been highlighted regarding clinical trials,[27, 28] and the implications of 
under-representing older people in trials are clear: treatment efficacy and safety may vary by age 
making it difficult to assess the benefits and disadvantages of treatment in the elderly. Aetiological 
and prognostic research may also be substantially biased if younger-onset samples are used. Genetic 
and environmental causes or risk factors are likely to vary with age and many outcomes are strongly 
associated with age.[2-4] The effect of this selection bias on studies of factors which influence 
prognosis is less clear; it is conceivable that the importance of prognostic factors varies by age, but 
we are not aware of studies which have investigated such an interaction. Studies of disease 
mechanisms in PD may be less affected by such selection biases, but gene-related mechanisms of 
neurodegeneration may have more impact in younger patients and the interactions between PD 
pathology, normal ageing, and co-morbid neurodegenerative pathology may be more easily 
investigated in the elderly.  
 
This study has several strengths: we have systematically reviewed incidence studies, the only study 
type which provides unbiased data on the age at inception. We have also considered the effects of 
heterogeneity on the results. There are nevertheless some limitations. Fundamentally, defining PD 
onset is difficult as non-motor symptoms often precede motor onset by many years[29] and recall of 
motor onset may be inaccurate. Additionally, individual studies had varying quality and variable 
case-finding intensity, and we did not assess the effect of this on study heterogeneity, because 
measuring study quality objectively is difficult. The included studies were predominantly from 
developed countries, limiting generalisability to other countries, but age-stratum-specific incidence-
rates can easily be applied to different age structures. Our separate pooled estimates of age at onset 
and age at diagnosis must be interpreted with caution because few studies reported both and there 
was high heterogeneity between studies, but age at onset was lower than age at diagnosis, as 
expected. The review of the age at inception in published research studies was limited to a small 
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number of journals over six consecutive months, but we believe this is representative of recent 
research in PD.  
 
What should be done to solve the problem of under-representativeness of research in PD? While it is 
possible to recruit maximally-representative samples for research by recruiting as many incident or 
prevalent cases as possible from the population, this is often unrealistic as it is time-consuming, 
resource-intensive, and particular research procedures may be unsuitable for many frail, elderly, or 
cognitively-impaired subjects. Nevertheless, we believe that there is a strong argument that studies 
of prognosis/outcomes in PD should be derived from population-representative cohorts, ideally 
long-term follow-up of incident cohorts: high-quality research should use the best methodology to 
answer the research question.[30, 31] Furthermore, we suggest the following recommendations for 
all studies of PD: (i) researchers should attempt to recruit age-representative patient samples for 
studies where possible; (ii) authors should report the mean age of onset/diagnosis; (iii) authors 
should discuss potential implications of age-unrepresentativeness in terms of bias and external 
validity; and (iv) reviewers and editors should consider the impact of this issue when reviewing and 
publishing manuscripts. 
 
In conclusion, PD is predominantly a disease of the elderly with a mean age of onset/diagnosis PD 
about 70. The true age at inception may be higher than this due to under-diagnosis in the elderly. 
Many published studies use age-unrepresentative subjects and the effect of this selection bias 
deserves further study. These issues deserve wider awareness from researchers, authors, reviewers, 
editors, and policy makers. We lastly propose that mean age at diagnosis is a simple and quick way 
to assess the representativeness of the patient sample in a research study. 
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Figure Captions 
 
Figure 1 
Random-effects meta-analysis of mean age at either onset or diagnosis in 17 studies of the incidence 
of Parkinson’s disease.  
 
Figure 2 
Random-effects meta-analysis of incidence rates in 10-year age strata in 12 whole-population 
incidence studies in Parkinson’s disease. 
 
Figure 3 
Pooled summary estimates of incidence rates from random-effects meta-analyses comparing whole 
population incidence studies (blue crosses) and in screening studies restricted to older age groups 
(red circles).  
 
Supplementary Figure 1 
Flowchart of included studies. 
 
Supplementary Figure 2 
Histogram of frequency of the age of inception of Parkinson’s disease derived from age-stratum-
specific incidence rates, standardised to the WHO standard European population.  
 
Supplementary Figure 3 
Random-effects meta-analysis of population-screening incidence studies in the elderly. Note: the 
scale is different from Figure 2.  
 
Supplementary Appendix 1: Search strategies 
 
Period 1, up to March 2009  
Medline search strategy 
1 Exp parkinsonian disorders/ 
2 Parkinson$.tw. 
3 1 or 2 
4 incidence/ or incidence studies/ 
5 registries/ 
6 (incidence or incident or registr$ or register$).tw. 
7 4 or 5 or 6  
8 3 and 7 
9 *parkinson disease/ep 
10 exp *parkinson, secondary/ep 
11 9 or 10 
12 8 or 11 
 
Embase search strategy 
1 parkinson disease/ 
2 parkinson$.tw. 
3 1 or 2 
4 incidence/ 
5 epidemiological data/ 
6 population research/  
7 geographic distribution/ 
8 register/ 
9 (incidence or incident or register$ or registr$ or new cases).mp*  
10 4 or 5 or 6 or 7 or 8 or 9  
11 3 and 10 
12 *parkinson disease/ep 
13 11 or 12 
 
Period 2, 2009 to September 2017 
Medline search strategy 
1. Parkinson’s disease/  
2. Parkinsonian disorders/ 
3. Parkinson$.tw. 
4. 1 or 2 or 3  
5. Incidence/ 
6. Cohort studies/  
7. Incidence.tw. 
8. Epidemiology.tw.  
9. Registries/ 
10. Register$.tw. 
11. 8 or 9 or 10  
12. 4 and 11 
13. Parkinson disease/ep  
14. 12 or 13 
15. Animals not humans 
16. 15 not 16 
 
Embase search strategy 
1. Parkinson disease/ 
2. Parkinsonism/ 
3. Parkinson$.tw. 
4. 1 or 2 or 3 
5. Incidence/ 
6. Incidence.tw. 
7. Epidemiology/ 
8. Epidemiology.tw. 
9. Registry/ 
10. Regist$.tw. 
11. 5 or 6 or 7 or 8 or 9 or 10 
12. 4 and 11 
13. Parkinson disease/ep  
14. 12 or 13 
15. Animals not humans/ 
16. 14 not 15 
Supplementary appendix 2: Quality criteria 
Study 
1. Whole 
population 
or random 
sample 
2. Pop size <1 
million with 
total person-
years >1 
million 
3. 
Prospective? 
4. Multiple 
sources to 
identify cases, 
including 
community 
5. Review by 
study specialist 
to confirm 
diagnosis >70% 
of cases 
6. Incidence 
defined by 
diagnosis (except 
for screening 
studies) 
7. 
Appropriate 
diagnostic 
criteria 
8. FU by 
study 
specialist to 
review 
diagnosis 
9. 
Adequate 
reporting 
10. Clear 
separation of 
incident and 
prevalent cases 
Total 
number of 
criteria 
met 
Morens 1996 0 0 1 1 1 1 1 0 1 1 7 
Granieri 1991 1 1 0 1 1 0 1 0 1 1 7 
Bower 1999 1 0 0 1 0 0 1 0 0 1 4 
Wang 1991  1 0 1 1 1 1 1 0 0 0 6 
Fall 1996 1 0 0 1 1 0 1 0 0 0 4 
Sutcliffe 1995 1 1 0 1 1 0 1 0 0 0 5 
Kuopio 1999 1 0 0 1 0 0 1 0 1 0 4 
Mayeux 1995 1 0 1 1 1 0 1 0 1 1 7 
Kusumi 1996 1 0 0 1 0 0 1 0 0 0 3 
Taba 2003) 1 1 1 1 1 0 1 0 0 1 7 
Cockerell 1996  1 0 1 0 0 0 0 0 0 1 3 
Chen 2001 1 0 1 1 0 1 1 0 0 1 6 
Van Den Eeden 2003 0 0 0 0 0 1 1 0 1 1 4 
Vines 1999 1 1 0 1 0 1 1 0 1 0 6 
MacDonald 2000 1 0 1 1 1 1 1 0 0 1 7 
Foltynie 2004) 1 1 1 1 1 1 1 0 1 1 9 
Alves 2009 1 0 1 1 1 1 1 0 1 1 8 
Mehta 2007 1 0 0 0 0 1 0 0 1 1 4 
Tan 2007 1 0 0 1 0 1 0 0 1 1 5 
Wermuth 2008 1 0 0 1 0 1 1 0 0 0 4 
Caslake 2013 1 1 1 1 1 1 1 1 1 1 10 
Hristova 2009 1 1 1 1 1 1 1 0 1 1 9 
Yamawaki 2009 1 0 0 0 0 0 1 0 0 0 2 
Das 2010 1 0 1 1 1 0 1 1 1 1 8 
Linder 2010 1 0 1 1 1 1 1 1 1 1 9 
Winter 2010 1 0 1 1 1 0 1 1 1 1 8 
Bauso 2012 1 0 0 0 0 1 1 0 1 1 5 
Savica 2013 1 1 0 1 0 0 1 0 1 1 6 
Duncan 2014 1 1 1 1 1 1 1 1 1 1 10 
Gordon 2015 1 1 0 0 0 1 1 0 1 0 5 
Evans 2016 1 1 1 1 1 1 1 1 0 1 9 
De Lau 2004 1 0 1 1 1 1 1 1 1 1 9 
Baldereschi 2000 1 0 1 1 0 1 1 0 1 1 7 
Benito-Leon 2004 1 0 1 1 0 1 1 0 1 1 7 
Perez 2010 1 0 1 1 0 1 1 0 0 1 6 
Derweesh 2016 1 0 1 1 1 1 1 0 1 1 8 
 
Quality criteria are based on the features of a good incidence study described by Twelves et al 2003 and the quality criteria for incidence or prevalence studies suggested by 
Loney et al 1998. 
 
Descriptors of quality criteria: 
1. Whole population studied or random sample drawn from whole population. 
2. Study population size <1 million with total person-years >1 million. 
3. Prospective study.  
4. Multiple sources used to identify cases, with methods identifying cases in the community as well as in hospital. 
5. Review by study specialist to confirm diagnosis in at least 70% of cases. Review by treating physicians was not sufficient to meet this criterion. 
6. Incidence defined by diagnosis (except for screening studies in which definition by onset is more appropriate. 
7. Appropriate diagnostic criteria 
8. Follow-up by study specialist to review diagnosis.  
9. Adequate reporting (population described, incident cases and denominator described by age stratum, confidence intervals reported for incidence rates). 
10. Appropriate methods used to ensure prevalent cases not included in incidence rate. 
Journal Year Month First author
Mean age at onset 
or diagnosis (NS= 
not stated
Movement Disorders 2016 December Willis 77.5
Movement Disorders 2016 December Lord 68.5
Movement Disorders 2016 December Delval 58.3
Movement Disorders 2016 December Wessel NS
Movement Disorders 2016 December Polli 56.1
Movement Disorders 2016 December Goetz NS
Movement Disorders 2016 December Hughes NS
Movement Disorders 2016 December Tan 60.0
Movement Disorders 2016 December Svensson 73.0
Movement Disorders 2016 December Pyle NS
Movement Disorders 2016 December Foo 63.7
Movement Disorders 2016 December Mangesius 58.6
Movement Disorders 2016 November Berman 56.0
Movement Disorders 2016 November Varanda 59.0
Movement Disorders 2016 November Neumann 49.0
Movement Disorders 2016 October Macleod 72.5
Movement Disorders 2016 October Rascol 61.5
Movement Disorders 2016 October Tessitore 60.5
Movement Disorders 2016 October Huppertz 56.9
Movement Disorders 2016 October Malek 66.2
Movement Disorders 2016 October Mirelman 59.0
Movement Disorders 2016 October Majbour 59.4
Movement Disorders 2016 October Fraser 57.0
Movement Disorders 2016 October Hirschmann 58.7
Movement Disorders 2016 October Antunes 60.9
Movement Disorders 2016 October Mestre 48.0
Movement Disorders 2016 October Kim NS
Movement Disorders 2016 October van Uem 52
Movement Disorders 2016 September LeWitt 52.9
Movement Disorders 2016 September Hauser NS
Movement Disorders 2016 September Tison 52.3
Movement Disorders 2016 September Fleury 50.0
Movement Disorders 2016 September Malkneccht 53.0
Movement Disorders 2016 September Rossi 64.1
Movement Disorders 2016 September Nakamura 61.5
Movement Disorders 2016 September Svenningsson NS
Movement Disorders 2016 September Sankar NS
Movement Disorders 2016 August Zhang 56.7
Movement Disorders 2016 August McIntosh NS
Movement Disorders 2016 August Dams NS
Movement Disorders 2016 August Marras 58.7
Movement Disorders 2016 August Nackaerts 55.6
Movement Disorders 2016 August Steigerwald NS
Movement Disorders 2016 August Marras NS
Movement Disorders 2016 July Shrestha 69.0
Movement Disorders 2016 July Flores-Cuadrado 56.3
Movement Disorders 2016 July Williams-Gray 65.8
Movement Disorders 2016 July Caviness NS
Movement Disorders 2016 July Loane NS
Movement Disorders 2016 July Kluger NS
Movement Disorders 2016 July Trenkwalder NS
Movement Disorders 2016 July Trenkwalder NS
Movement Disorders 2016 July Breen 63.4
Parkinsonism & Related Disorders 2016 December Fisher 59.1
Parkinsonism & Related Disorders 2016 December Zhu 50.5
Parkinsonism & Related Disorders 2016 December Lucas-Jimenez 61.0
Parkinsonism & Related Disorders 2016 December Merola 58.6
Parkinsonism & Related Disorders 2016 December Rolston NS
Parkinsonism & Related Disorders 2016 December Vanbellingen 61.4
Parkinsonism & Related Disorders 2016 December Bernhardt NS
Parkinsonism & Related Disorders 2016 December Boel 48.5
Parkinsonism & Related Disorders 2016 December Lawton 66.1
Parkinsonism & Related Disorders 2016 December Mills 62.2
Parkinsonism & Related Disorders 2016 December Mills 59.3
Parkinsonism & Related Disorders 2016 December Tatura NS
Parkinsonism & Related Disorders 2016 December Dan 57.3
Parkinsonism & Related Disorders 2016 December Wills NS
Parkinsonism & Related Disorders 2016 November Biernacka NS
Parkinsonism & Related Disorders 2016 November Fielding 71.9
Parkinsonism & Related Disorders 2016 November Ricciardi 60.6
Parkinsonism & Related Disorders 2016 November Unger 60.9
Parkinsonism & Related Disorders 2016 November Hattori 60.2
Parkinsonism & Related Disorders 2016 November Martino NS
Parkinsonism & Related Disorders 2016 November lee 61.3
Parkinsonism & Related Disorders 2016 November Moccia 62.8
Parkinsonism & Related Disorders 2016 November Hand 69.4
Parkinsonism & Related Disorders 2016 November Kotagal 58.6
Parkinsonism & Related Disorders 2016 October Tacik 67.0
Parkinsonism & Related Disorders 2016 October Foo 60.7
Parkinsonism & Related Disorders 2016 October Lee 67.1
Parkinsonism & Related Disorders 2016 October Ucak NS
Parkinsonism & Related Disorders 2016 October Goldstein 58.2
Parkinsonism & Related Disorders 2016 October Rajput 70.8
Parkinsonism & Related Disorders 2016 October Siepmann NS
Parkinsonism & Related Disorders 2016 September Krishnamoorthy 49.1
Parkinsonism & Related Disorders 2016 September Schiehser 59.1
Parkinsonism & Related Disorders 2016 September Premi 66.1
Parkinsonism & Related Disorders 2016 September Narayanaswami NS
Parkinsonism & Related Disorders 2016 August Palhagen 51.8
Parkinsonism & Related Disorders 2016 August Goh 67.3
Parkinsonism & Related Disorders 2016 August Yang 57.7
Parkinsonism & Related Disorders 2016 August Arnaldi 70.4
Parkinsonism & Related Disorders 2016 August Sleeman 71.8
Parkinsonism & Related Disorders 2016 August Wang 59.4
Parkinsonism & Related Disorders 2016 August Pereira NS
Parkinsonism & Related Disorders 2016 August Rektorova 58.2
Parkinsonism & Related Disorders 2016 August Cilia 52.0
Parkinsonism & Related Disorders 2016 August Merola 49.8
Parkinsonism & Related Disorders 2016 August Rengmark 57.8
Parkinsonism & Related Disorders 2016 August Mengel 60.0
Parkinsonism & Related Disorders 2016 July Svensson NS
Parkinsonism & Related Disorders 2016 July Zhang 58.4
Parkinsonism & Related Disorders 2016 July Simuni 60.6
Parkinsonism & Related Disorders 2016 July Peretz 71.3
Parkinsonism & Related Disorders 2016 July Vervoort 53.8
Parkinsonism & Related Disorders 2016 July Maskova 34.5
Parkinsonism & Related Disorders 2016 July Podgorny 62.0
Parkinsonism & Related Disorders 2016 July Warnecke 58.0
Parkinsonism & Related Disorders 2016 July Ruzicka 55.0
Parkinsonism & Related Disorders 2016 July Shih 66.6
Parkinsonism & Related Disorders 2016 July Macleod 72.5
Parkinsonism & Related Disorders 2016 July van Balkom 58.0
Parkinsonism & Related Disorders 2016 July Erro 63.2
Parkinsonism & Related Disorders 2016 July Kaipa NS
Parkinsonism & Related Disorders 2016 July Choubtum NS
Brain 2016 October Kinan 61.4
Brain 2016 September Accolla 47.3
Brain 2016 September Maillet 57.1
Brain 2016 August Rae 59.6
Brain 2016 August Kondylis NS
Brain 2016 August Rolinski 65.2
Brain 2016 August Rae 59.6
Brain 2016 July Hansen 62.6
Brain 2016 July Masellis 57.7
Neurology 2016 December Pyatigorskaya 53.5
Neurology 2016 December Pagano 56.8
Neurology 2016 November Mattis NS
Neurology 2016 November Brys 54.5
Neurology 2016 October Bjornestad 67.5
Neurology 2016 October Morgante 
Neurology 2016 September Barichella 60.9
Neurology 2016 August Burciu 60.9
Neurology 2016 August Gibbons 56.81785714
Neurology 2016 July Mollenhauer 61.59166667
JNNP 2016 December Little 47
JNNP 2016 November Swallow 66.2
JNNP 2016 October Kraemmer 64.51416667
JNNP 2016 October McMillen 61
JNNP 2016 September Moisan 76
JNNP 2016 September Evans 68.6
JNNP 2016 August Smith 61.7
JNNP 2016 July Yamada 53.5
JNNP 2016 July Little 41.8
Excluded? Reason for exclusion, if applicable
Excluded Only 60+
Excluded DBS patients
Excluded DBS patients
Excluded DBS patients
Excluded Patietns treated with DBS
Excluded Patients with dyskinesias (more common in young-onset PD)
Excluded Patietns treated with DBS
Excluded Patients treated with DBS
Excluded Advanced therapies paper
Excluded Patients treated with DBS
Excluded Some age restriction
Excluded Patietns treated with DBS
Excluded Patietns treated with DBS
Excluded Data not available for PD separately from other causes of parkinsonism
Excluded Cases of conjugal PD
Excluded Patients with LCIG
Excluded Restricted to 45-75 yrs at inclusion
Excluded Advanced therapies paper
Excluded Early-onset PD
Excluded Patietns treated with DBS
Excluded Patients age-matched to idiopathic RBD patients
Excluded Parkin-associated
Excluded Patietns treated with DBS
Excluded Patietns treated with DBS
Study 
Geographical area 
(Populaton size) 
Incidence 
period 
Sources to identify 
possible cases 
Methods of case 
identification 
(% possible cases 
examined by study 
specialist) 
Definition 
of incident 
cases 
Diagnostic criteria Prospective? Quality 
assessment 
score 
Number of 
cases 
Crude 
incidence 
rate per 
100,000 
person 
years (95% 
CI) 
Mean age at 
inception 
(95% CI) 
Morens 19961 
Hawaii 
(Cohort of 8,006 
men aged 45-95) 
1965-1994 Medical records (hospital, 
neurology), death certificates, 
re-screening of cohort with 
questionnaire, examination 
Case notes review 
Examination by 
neurologist 
(NS) 
Diagnosis ≥2 cardinal signs, 
improvement after 
levodopa, relevant 
exclusions 
Partial 7 92 11.1  NS 
Granieri 19912 
Ferrara, Italy  
(187,381) 
1967-1987 Medical records (hospital, 
rehabilitation centres, 
neurology); health insurance 
records; nursing homes; drug 
prescriptions; GP telephone 
survey 
Case notes review 
Examination by 
neurologist 
(32) 
Onset ≥2 of 4 cardinal signs, 
progressive 
deterioration, relevant 
exclusions 
No 7 394 
 
10.0 (9.1-
11.1) 
62.6 (61.7–
63.5) at 
onset 
Bower 19993 
Olmsted County,  
USA  
(NS) 
1976-1990 Medical records (Mayo clinic 
record linkage) 
Case notes review 
(0) 
Onset ≥2 of 4 cardinal signs, 
all of: (i) response to 
levodopa, (ii) no 
prominent/early signs 
of atypical syndrome, 
(iii) no secondary cause 
No 4 154 
 
10.8 NS 
Wang 19914 
China  
(3,869,162) 
1986 Door-to-door questionnaire 
distributed by medical 
workers 
Examination by 
neurologist 
(100) 
Diagnosis Insidiously progressive 
rest tremor, rigidity, 
hypokinesia, cases 
without definite cause, 
onset after middle age. 
Relevant exclusions 
Yes 6 58 1.5 NS 
Fall 19965 
Southeast Sweden 
(147,777) 
1986-1988 Medical records (neurology); 
inquiries to all neurologists, 
geriatricians, GPs; drug 
prescriptions; nursing homes 
Case notes review 
Examination by 
neurologist if not 
previously seen by 
expert 
(NS) 
Onset All of: (i) At least 1 of: 
tremor, rigidity, 
hypokinesia, (ii) 
progression, (iii) no 
neuroleptics (iv) 
response to levodopa 
No 4 49 11 
 
65.6 (63.7–
67.5) at 
onset 
 
Sutcliffe 19956 
Northampton, UK 
(298,985) 
 
1986-1990 Medical records (hospital), 
enquiries to GPs, consultants 
Examination by 
neurologist of all 
patients consented, 
Case notes review of 
those refusing 
(89) 
Onset UKPDBB criteria No 5 175 12 NS 
Kuopio 19997 
Turku, Finland  
(196,864) 
1987-1991 Medical records (neurology, 
hspital), Finnish PD 
association, residential homes 
Inquiries to health centres, 
social insurance records 
Case notes review and 
examination by 
neurologist of doubtful 
cases 
(39) 
NS UKPDBB criteria No 4 NS 17.2 NS 
Mayeux 19958 1989-1991 Medical records (HMO, Examination by Onset UKPDBB criteria Yes 7 83 13 (10.2- 76.3 (74.3-
Study 
Geographical area 
(Populaton size) 
Incidence 
period 
Sources to identify 
possible cases 
Methods of case 
identification 
(% possible cases 
examined by study 
specialist) 
Definition 
of incident 
cases 
Diagnostic criteria Prospective? Quality 
assessment 
score 
Number of 
cases 
Crude 
incidence 
rate per 
100,000 
person 
years (95% 
CI) 
Mean age at 
inception 
(95% CI) 
Manhattan,USA 
(NS) 
hospital, private GP, 
neurology); social services; 
disability / pension records; 
nursing homes; health 
Insurance records 
neurologist to confirm 
diagnosis 
(100) 
15.8) 78.3) at 
diagnosis 
75.2 (73.2-
77.2) at 
onset 
Kusumi 19969 
Yonago City, Japan 
(132,315) 
1989-1992 Medical records (hospital); 
questionnaire (other hospitals, 
medical practitioners), 
disability records, death 
certificates 
Not specified 
(0) 
Onset ≥ 2 of 4 cardinal signs, 
Improvement after 
levodopa, and relevant 
exclusions 
No 3 79 5 70.4 (68.5-
72.3) at 
onset 
Taba 200310 
Tartu, Estonia 
(156,417) 
1990-1998 Neurology and neurosurgery 
records reviewed yearly, GPs 
asked to notify, nursing homes 
and regional hospitals visited, 
PD Society contacted, 
prescription data 
Examination by 
neurologist 
(100) 
Onset UKPDBB criteria Yes 7 264 18.8 68.8 (67.7-
69.9) at 
onset 
Cockerell 199611 
London, UK 
(26,636) 
1993 Recording of GPs 
consultations for neurological 
problems, GP notes screening 
in a proportion 
Review of information 
sent by GP, Neurology 
referral encouraged 
(NS)  
NS NS Yes 3 7 PD 26 
 
NS 
Chen 200112 
Ilan County, Taiwan 
(75,579) 
1993-1997 Door-to-door questionnaire 
+/- examination to identify 
people without Parkinsonism 
at baseline. New cases then 
identified from Bureau of 
National Health Insurance 
records 
Case notes review 
(0) 
Diagnosis ≥ 2 of 4 cardinal signs 
plus exclusions 
Yes 6 15 10.4 NS 
Van Den Eeden 
200313 
Northern California, 
USA 
(4,776,038 person-
years) 
1994-1995 Regular surveillance of 
computer databases 
(outpatient/inpatient 
utilization/billing, pharmacy); 
notification of all neurologists 
asking for referrals 
Case notes review by 
movement disorders 
specialist 
(0) 
Diagnosis Modified CAPIT/Hughes 
diagnostic criteria 
No 4 588 12.3 70.5 (70.2–
73.8) at 
diagnosis 
Viñes 199914 
Navarra, Spain 
(523,563) 
1994-1995 Medical records (neurologists,  
GPs); questionnaire to 
neurologists; telephone 
inquiries to residential care 
doctors 
Case notes review 
(NS) 
Diagnosis UKPDBB criteria Unclear 6 86 8.21 PD 69.5 
(67.9-71.3) 
at onset 
MacDonald 200015 
London, UK 
1995-1996  Medical records (all GP notes 
screened, hospital); drug 
GP case notes review, 
examination by 
Diagnosis ≥ 2 of 4 cardinal signs 
with relevant exclusions 
Yes 7 NS 19 NS 
Study 
Geographical area 
(Populaton size) 
Incidence 
period 
Sources to identify 
possible cases 
Methods of case 
identification 
(% possible cases 
examined by study 
specialist) 
Definition 
of incident 
cases 
Diagnostic criteria Prospective? Quality 
assessment 
score 
Number of 
cases 
Crude 
incidence 
rate per 
100,000 
person 
years (95% 
CI) 
Mean age at 
inception 
(95% CI) 
(100,230) prescriptions; GP referrals 
(any neurological cases) to 
linkage clinic; enquiries to GPs; 
GP databases 
neurologist  
(100) 
Foltynie 200416 
Cambridgeshire, UK 
(700,000) 
2000-2002 Regular requests to, GPs, 
neurologists, geriatricians, PD 
nurses; hospital discharge 
coding; advertising through PD 
Society 
Examination by 
neurologist 
(77) 
Diagnosis UKPDBB criteria Yes 9 201 13.6 (11.8-
15.6) 
72.0 (70.2-
73.8) at 
diagnosis 
Alves 200917 
Western Norway 
(1,052,075) 
2004-2006 Direct referral with email 
reminders (GP, hospital 
doctors); nursing homes; 
medical records (hospital, GP); 
hand search of referrals 
Examination by study 
neurologist 
(99.8) 
Diagnosis ≥2 of 4 cardinal signs 
with relevant exclusions 
Yes 8 265 13.7 (12.2-
15.5) 
69.4 (68.4-
70.4) at 
diagnosis 
Wermuth 200818 
Faroe Islands 
(45,878) 
1995-2005 Direct referral with reminders 
(GP, Neurologists), drug 
register, self-referral, press 
release 
Examination by study 
neurologist 
(66.7) 
Diagnosis ≥2 of 3 cardinal signs 
without secondary 
cause 
No 4 97 21.1 (17.3-
25.8) 
66.0 at 
onset 
Caslake 201319 
Aberdeen, UK 
(317,357 [Pilot phase 
148,600]) 
2002-2004; 
2006-2009 
Direct referral with email 
reminders to GPs, hospital 
doctors; medical records 
(hospital, GP); hand search of 
referrals 
Examination by study 
neurologist 
(97.7) 
Diagnosis ≥2 of 4 cardinal signs, 
clinical diagnosis of PD, 
not drug-induced 
Yes 10 201 17.5 (15.1-
19.9) 
72.3 (70.9-
73.7) at 
diagnosis  
Hristova 201020 
Southern Bulgaria 
(713,090) 
2002-2004 Repeated survey with a 
validated questionnaire; 
nursing home surveys; medical 
records from regional 
hospitals. 
Examination by a 
specialist plus ancillary 
tests 
(100) 
Diagnosis UKPDBB criteria plus 
levodopa challenge 
Yes 9 244 11.4 (10.1-
13.0) 
68 (66-70) at 
onset 
Yamawaki 200921 
Western Japan 
(113,191) 
2000-2004 Medical records (hospital); 
questionnaire to other 
hospitals and medical 
practitioners, disability 
records, death certificates 
Not specified 
(0) 
Onset UKPDBB criteria No 2 254 18.7 (11.3–
25.5) 
68.7 (67.4-
70.0) at 
onset 
Das 201022 
Kolkata, India 
(100,802) 
2003-2007 Repeated survey of the study 
population selected through 
stratified random and 
alternate sampling, validated 
questionnaire. 
Examination by a 
specialist 
(100) 
Onset UKPDBB criteria Yes 8 23 4.56 (2.87- 
7.51) 
NS 
Linder 201023 
Umea, Sweden 
2004-2007 Direct referral with email 
reminders to GPs, hospital 
Examination by a 
specialist, 
Diagnosis UKPDBB criteria Yes 9 112 19.7 (16.1–
23.3) 
70.8 (68.9-
72.7) at 
Study 
Geographical area 
(Populaton size) 
Incidence 
period 
Sources to identify 
possible cases 
Methods of case 
identification 
(% possible cases 
examined by study 
specialist) 
Definition 
of incident 
cases 
Diagnostic criteria Prospective? Quality 
assessment 
score 
Number of 
cases 
Crude 
incidence 
rate per 
100,000 
person 
years (95% 
CI) 
Mean age at 
inception 
(95% CI) 
(141,950) 
 
doctors, nursing homes; hand 
searching of GP outpatient 
referrals; survey of nursing 
homes; medical records 
neuroimaging, second 
specialist opinion 
where necessary.  
(100) 
diagnosis 
Winter 201024 
Moscow 
(1,237,900) 
2006-2008 Medical Record Direct referral 
with email reminders GP, 
Hospital doctors, Nursing 
homes. 
Examination by 
specialist performed, 
neuroimaging 
(100) 
Onset UKPDBB criteria Yes 8 308 9.95 (8.87 – 
11.13) 
64.6 (63.5-
65.7) at 
onset 
Bauso 201225 
Buenos Aires, 
Argentina 
(140,000) 
2003-2008 Medical Record 
Drug register 
Database searches. 
Case note review and 
further information 
from treating doctors 
(0) 
Diagnosis UKPDBB criteria No 5 239 31.2 (27.4-
35.4) 
71.5 (70.1-
72.9) at 
diagnosis 
Savica 201326 
Olmsted County, 
USA 
(NS) 
1991-2005 Medical records linkage 
system, Rochester 
Epidemiology Project 
Review of medical 
records 
(0) 
Onset ≥2 cardinal signs with 
relevant exclusions 
No 6 264 14.2 (12.6-
16.0) 
71 (69-73) at 
diagnosis 
Duncan 201427 
Newcastle, UK 
(488,576) 
2009-2011 GP, neurologist, geriatrician 
and PD nurse specialist 
referrals, regular reminders; 
screening of GP lists 
Examination by 
specialist + FP-CIT 
SPECT if unclear 
(NS) 
Diagnosis UKPDBB criteria Yes 10 155 15.9 (13.4-
18.4) 
72.4 (70.8-
74.0) at 
diagnosis 
Gordon 201528 
Navajo Nation, USA 
(200,000) 
2002-2011 
 
Database searches. 
Drug register 
 
Case note review and 
contact with managing 
physician 
(0) 
Diagnosis UKPDBB criteria No 5 524 22.5 (20.7-
24.5) 
74 (IQR 66-
80) at 
diagnosis 
Evans 201629 
Cambridgeshire, UK 
(approx. 620,000) 
2008-2010 Screen of NHS referrals, 
contacting GPs and hospital 
specialists,  
Examination by 
neurologist 
Diagnosis UKPDBB criteria Yes 9 173 15.9 (13.8-
18.2) 
68.6 at 
diagnosis 
(67.6 at 
onset) 
Screening studies in older age groups 
De Lau 200430 
Rotterdam, The 
Netherlands 
(6,839 aged 55 years 
or over) 
1990-1999 In person screening of whole 
cohort (78% completed 
screening) at baseline and 
follow-up (mean follow-up 5.8 
years). Also computer linkage 
to GP and pharmacy records. 
Examination by 
neurologist 
(87) 
 
Midpoint 
between 
examination 
at which 
parkinsonian, 
and prev 
examination 
≥2 of 4 cardinal signs 
with relevant exclusions 
Yes  8 67 174 (140-
220) 
 
Baldereschi 200031 
Italy 
(4,341 aged 65-84 
years) 
1992-1996 In person screening of random 
sample of population at 
baseline (82% completed 
screening) and follow-up 
Examination by 
neurologist 
(NS) 
Onset ≥2 of 4 cardinal signs 
with relevant exclusions 
 
Yes 7 42 346 (241-
450) 
 
Study 
Geographical area 
(Populaton size) 
Incidence 
period 
Sources to identify 
possible cases 
Methods of case 
identification 
(% possible cases 
examined by study 
specialist) 
Definition 
of incident 
cases 
Diagnostic criteria Prospective? Quality 
assessment 
score 
Number of 
cases 
Crude 
incidence 
rate per 
100,000 
person 
years (95% 
CI) 
Mean age at 
inception 
(95% CI) 
(mean follow-up 3.9 years). 
Also data from records, 
relatives and GPs 
Benito-Leon 200432 
Central Spain 
(5,160 aged 65 years 
or over) 
1994-1998 Screening of whole cohort 
using questionnaire at 
baseline (71% completed 
screening)and follow-up 
(mean follow-up 3 years). Also 
computer linkage to GP and 
pharmacy records. 
Structured clinical 
work-up by 
neurologists, then 
discussion by panel of 
3 senior neurologists 
(27) 
Onset UKPDBB criteria Yes 7 17 133 (83-
215) 
 
Mehta 200733 
Blue Mountains, 
Australia 
(2,545) 
1992-2002 Repeated cross- sectional 
survey in residents aged 49 
years and older. 
Case notes review 
(0) 
Diagnosis Clinical features 
consistent with PD 
 
No 
4 19 81 (44-117)  
Perez 201034 
Gironde and 
Dordogne, France 
(3777 aged 65 and 
over) 
15 years 
from c. 1988 
Repeated in-person screening 
of random sample of cohort at 
baseline (68% completed 
screening) and repeated 
follow-up up to 15 years.  
GP and specialist 
records reviewed if 
screen positive. Some 
reviewed by study 
neurologist 
(~60) 
Onset UKPDBB criteria Yes 6 68 263 (207-
334) 
 
Darweesh 201635 
Rotterdam, 
Netherlands (4472 
aged 55 or over) 
2000-2011 In person screening of whole 
cohort (78% completed 
screening) at baseline and 
follow-up). Also computer 
linkage to GP and pharmacy 
records. 
UPDRS examination 
and review by 
neurologist 
Onset Good treatment 
response or positive 
DaTSCAN or diagnosis 
confirmed by a 
neurologist with 
exclusions for 
secondary parkinsonism 
Yes 8 10 45 (22-83)  
 
CI = confidence interval; NS = not stated; UKPDBB = United Kingdom Parkinson’s Disease Brain Bank; UPDRS = Unified Parkinson’s disease rating scale. 
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Journal 
Number of 
articles with a 
general sample 
of Parkinson’s 
disease 
Number of 
these articles 
reporting age 
at onset or 
age at 
diagnosis 
Median of 
reported mean 
ages at 
inceptiona 
(IQR) 
Mean of 
reported mean 
ages at 
inceptiona (SD) 
Range of 
mean age at 
inceptiona 
Parkinsonism & 
Related 
Disorders 
55 43 60.6 (58.2–
66.1) 
61.5 (5.7) 49.1–72.5 
Movement 
Disorders 
42 29 59.0 (56.7–
63.4) 
60.2 (5.3) 52.0–73.0 
Neurology 9 8 58.9 (55.7–
61.2) 
59.1 (4.6) 53.5–67.5 
Journal of 
Neurology, 
Neurosurgery & 
Psychiatry 
7 7 64.5 (56.7–
63.4) 
64.5 (5.3) 53.5–76.0 
Brain 7 7 59.6 (57.1–
61.4) 
57.9 (5.1) 47.3–62.6 
All five journals 
combined 
120 94 60.4 (57.5–
63.7) 
60.8 (5.6) 47.3-76.0 
aEither age at diagnosis or age at disease onset. 
